130 related articles for article (PubMed ID: 33385520)
1. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data
Di Filippo Y; Dalle S; Mortier L; Dereure O; Dalac S; Dutriaux C; Leccia MT; Legoupil D; Saiag P; Brunet-Possenti F; Arnnault JP; Maubec E; Granel-Brocard F; De Quatrebarbes J; Aubin F; Lesimple T; Beylot-Barry M; Stoebner PE; Dupuy A; Stephan A; Grob JJ; Lefevre W; Oriano B; Allayous C; Lebbé C; Montaudié H
Ann Oncol; 2021 Apr; 32(4):542-551. PubMed ID: 33385520
[TBL] [Abstract][Full Text] [Related]
2. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA
Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192
[TBL] [Abstract][Full Text] [Related]
3. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study.
Rutkowski P; Indini A; De Luca M; Merelli B; Mariuk-Jarema A; Teterycz P; Rogala P; Lugowska I; Cybulska-Stopa B; Labianca A; Di Guardo L; Del Vecchio M; Pigozzo J; Randon G; Corti F; Tondini CA; Rulli E; Mandala M
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203662
[TBL] [Abstract][Full Text] [Related]
4. Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
Vallet A; Oriano B; Mortier L; Dalle S; Dutriaux C; Guillot B; Leccia MT; Dalac S; Saiag P; Lacour JP; Legoupil D; De Quatrebarbes J; Brunet-Possenti F; Lesimple T; Arnault JP; Aubin F; Granel-Brocard F; Stoebner PE; Maubec E; Dreno B; Allayous C; Porcher R; Lebbé C;
JAMA Dermatol; 2019 Jun; 155(6):673-678. PubMed ID: 31042256
[TBL] [Abstract][Full Text] [Related]
5. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.
Rousset P; Dalle S; Mortier L; Dereure O; Dalac S; Dutriaux C; Leccia MT; Legoupil D; Brunet-Possenti F; De Quatrebarbes J; Grob JJ; Saiag P; Maubec E; Stoebner PE; Granel-Brocard F; Arnault JP; Allayous C; Oriano B; Lebbe C; Montaudié H
J Am Acad Dermatol; 2023 Apr; 88(4):808-815. PubMed ID: 36543626
[TBL] [Abstract][Full Text] [Related]
6. The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients.
Donnelly D; Bajaj S; Yu J; Hsu M; Balar A; Pavlick A; Weber J; Osman I; Zhong J
J Immunother Cancer; 2019 Aug; 7(1):222. PubMed ID: 31426863
[TBL] [Abstract][Full Text] [Related]
7. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
8. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
Naik GS; Waikar SS; Johnson AEW; Buchbinder EI; Haq R; Hodi FS; Schoenfeld JD; Ott PA
J Immunother Cancer; 2019 Mar; 7(1):89. PubMed ID: 30922394
[TBL] [Abstract][Full Text] [Related]
9. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
Tétu P; Allayous C; Oriano B; Dalle S; Mortier L; Leccia MT; Guillot B; Dalac S; Dutriaux C; Lacour JP; Saiag P; Brunet-Possenti F; De Quatrebarbes J; Stoebner PE; Legoupil D; Beylot-Barry M; Lesimple T; Aubin F; Dreno B; Mohamed S; Ballon A; Porcher R; Lebbe C
Eur J Cancer; 2019 May; 112():38-46. PubMed ID: 30909072
[TBL] [Abstract][Full Text] [Related]
10. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
11. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
Nomura M; Oze I; Masuishi T; Yokota T; Satake H; Iwasawa S; Kato K; Andoh M
Int J Clin Oncol; 2020 May; 25(5):972-977. PubMed ID: 31938955
[TBL] [Abstract][Full Text] [Related]
12. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A
J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
14. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
[TBL] [Abstract][Full Text] [Related]
15. Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study.
Lee JH; Hyung S; Lee J; Choi SH
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002189
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic-pharmacodynamic real-life study.
Goldwirt L; Louveau B; Baroudjian B; Allayous C; Jouenne F; Da Meda L; Vu LT; Sauvageon H; Herms F; Delyon J; Lebbé C; Mourah S
Cancer Chemother Pharmacol; 2021 Sep; 88(3):427-437. PubMed ID: 34057572
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-life assessment in French patients with metastatic melanoma in real life.
Kandel M; Dalle S; Bardet A; Allayous C; Mortier L; Dutriaux C; Guillot B; Leccia MT; Dalac S; Legoupil D; Saiag P; Montaudie H; Arnault JP; Brunet-Possenti F; Grob JJ; DeQuatrebarbes J; Beylot-Barry M; Lesimple T; Aubin F; Maubec E; Granel-Brocard F; Stoebner PE; Dupuy A; Dreno B; Michiels S; Lebbe C; Borget I
Cancer; 2020 Feb; 126(3):611-618. PubMed ID: 31639198
[TBL] [Abstract][Full Text] [Related]
18. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
19. Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase).
Russo D; Dalle S; Dereure O; Mortier L; Dalac-Rat S; Dutriaux C; Leccia MT; Legoupil D; Montaudié H; Maubec E; De Quatrebarbes J; Arnault JP; Brocard FG; Saïag P; Dreno B; Allayous C; Oriano B; Lefevre W; Lebbé C; Boussemart L
Front Oncol; 2023; 13():1250026. PubMed ID: 37936607
[TBL] [Abstract][Full Text] [Related]
20. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort.
Carlet C; Dalle S; Leccia MT; Mortier L; Dalac-Rat S; Dutriaux C; Legoupil D; Montaudié H; Dereure O; De Quatrebarbes J; Granel-Brocard F; Le-Bouar M; Charles J; Brunet-Possenti F; Dreno B; Lefevre W; Allayous C; Lebbe C; Nardin C
J Am Acad Dermatol; 2022 Feb; 86(2):345-352. PubMed ID: 34153388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
